Cisplatin-induced ubiquitination of RNA polymerase II large subunit and suppression of induction by 7-hydroxystaurosporine (UCN-01)YANG, Li-Ying; HONG JIANG; RANGEL, Kelly M et al.Oncology reports. 2003, Vol 10, Num 5, pp 1489-1495, issn 1021-335X, 7 p.Article

Induction by staurosporine of hepatocyte growth factor production in human skin fibroblasts independent of protein kinase inhibitionYAGI, Yasuyuki; SOTANI, Tomohiro; NAGAO, Toshinori et al.Biochemical pharmacology. 2003, Vol 66, Num 9, pp 1797-1808, issn 0006-2952, 12 p.Article

Tissue distribution and plasma pharmacokinetics of UCN-01 at steady-state and following bolus administration in rats: Influence of human α₁-acid glycoprotein bindingHEDAYA, Mohsen A; DAOUD, Sayed S.Anticancer research. 2001, Vol 21, Num 6A, pp 4005-4010, issn 0250-7005Article

Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinomaRINI, Brian I; WEINBERG, Vivian; SHAW, Vanessa et al.Cancer. 2004, Vol 101, Num 1, pp 90-95, issn 0008-543X, 6 p.Article

Altered pharmacokinetics of a novel anticancer drug, UCN-01, caused by specific high affinity binding to α₁-Acid glycoprotein in humansFUSE, E; TANII, H; TAKAI, K et al.Cancer research (Baltimore). 1999, Vol 59, Num 5, pp 1054-1060, issn 0008-5472Article

Development of a highly sensitive high-performance liquid chromatographic method for measuring an anticancer drug, UCN-01, in human plasma or urineKURATA, N; KURAMITSU, T; TANII, H et al.Journal of chromatography. B, Biomedical sciences and applications. 1998, Vol 708, Num 1-2, pp 223-227, issn 1387-2273Article

UCN-01 and UCN-02, new selective inhibitors of protein kinase C. I: Screening, producing organism and fermentationTAKAHASHI, I; ASANO, K; KAWAMOTO, I et al.Journal of antibiotics (Tokyo. 1968). 1989, Vol 42, Num 4, pp 564-570, issn 0021-8820, 7 p.Article

Distinct roles for p53 transactivation and repression in preventing UCN-01-mediated abrogation of DNA damage-induced arrest at S and G₂ cell cycle checkpointsLEVESQUE, Aime A; KOHN, Ethan A; BRESNICK, Edward et al.Oncogene (Basingstoke). 2005, Vol 24, Num 23, pp 3786-3796, issn 0950-9232, 11 p.Article

Cell cycle-dependent potentiation of cisplatin by UCN-01 in non-small-cell lung carcinomaMACK, Philip C; GANDARA, David R; LAU, Alvin H et al.Cancer chemotherapy and pharmacology. 2003, Vol 51, Num 4, pp 337-348, issn 0344-5704, 12 p.Article

Potentiation of the anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the kinase inhibitor Staurosporine or its clinically relevant analogue UCN-01YEOW, W.-S; ZIAUDDIN, M. F; MAXHIMER, J. B et al.British journal of cancer. 2006, Vol 94, Num 10, pp 1436-1445, issn 0007-0920, 10 p.Article

Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human α₁-Acid glycoproteinFUSE, E; TANII, H; FIGG, W. D et al.Cancer research (Baltimore). 1998, Vol 58, Num 15, pp 3248-3253, issn 0008-5472Article

7-Hydroxystaurosporine (UCN-01) causes redistribution of proliferating cell nuclear antigen and abrogates cisplatin-induced S-phase arrest in Chinese hamster ovary cellsBUNCH, R. T; EASTMAN, A.Cell growth and differentiation. 1997, Vol 8, Num 7, pp 779-788, issn 1044-9523Article

Development of a simplified, sensitive high-performance liquid chromatographic method using fluorescence detection to determine the concentration of UCN-01 in human plasmaSMITH, Judith A; CORTES, Jorge; NEWMAN, Robert A et al.Journal of chromatography. B, Biomedical sciences and applications. 2001, Vol 760, Num 2, pp 247-253, issn 1387-2273Article

The effect of different dosing schedules of UCN-01 on its pharmacokinetics and cardiohaemodynamics in dogsKURATA, N; IMABEPPU, S; NITOH, M et al.Journal of pharmacy and pharmacology. 2000, Vol 52, Num 11, pp 1327-1335, issn 0022-3573Article

Blocking of glioma proliferation in vitro and in vivo and potentiating the effects of BCNU and cisplatin : UCN-01, a selective protein kinase C inhibitorPOLLACK, I. F; KAWECKI, S; LAZO, J. S et al.Journal of neurosurgery. 1996, Vol 84, Num 6, pp 1024-1032, issn 0022-3085Article

P21^CDKN1A allows the repair of replication-mediated DNA double-strand breaks induced by topoisomerase I and is inactivated by the checkpoint kinase inhibitor 7-hydroxystaurosporineFURUTA, T; HAYWARD, R. L; MENG, L.-H et al.Oncogene (Basingstoke). 2006, Vol 25, Num 20, pp 2839-2849, issn 0950-9232, 11 p.Article

Early development of cyclin dependent kinase modulatorsROY, K. K; SAUSVILLE, E. A.Current pharmaceutical design. 2001, Vol 7, Num 16, pp 1669-1687, issn 1381-6128Article

The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1BUSBY, E. C; LEISTRITZ, D. F; ABRAHAM, R. T et al.Cancer research (Baltimore). 2000, Vol 60, Num 8, pp 2108-2112, issn 0008-5472Article

Analogs of staurosporine : Potential anticancer drugs?GESCHER, A.General pharmacology. 1998, Vol 31, Num 5, pp 721-728, issn 0306-3623Article

Disposition in mice of 7-hydroxystaurospine, a protein kinase inhibitor with antitumor activityHILL, D. L; TILLERY, K. F; ROSE, L. M et al.Cancer chemotherapy and pharmacology. 1994, Vol 35, Num 1, pp 89-92, issn 0344-5704Article

Effect of UCN-01, a selective inhibitor of protein kinase C, on the cell-cycle distribution of human epidermoid carcinoma, A431 cellsAKINAGA, S; NOMURA, K; GOMI, K et al.Cancer chemotherapy and pharmacology. 1993, Vol 33, Num 4, pp 273-280, issn 0344-5704Article

UCN-01 inhibits p53 up-regulation and abrogates γ-radiation-induced G₂-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1QIANG YU; JIHYUN LA ROSE; HONGLIANG ZHANG et al.Cancer research (Baltimore). 2002, Vol 62, Num 20, pp 5743-5748, issn 0008-5472, 6 p.Article

Protein binding alters the activity of suramin, carboxyamidotriazole, and UCN-01 in an ex Vivo rat aortic ring angiogenesis assayKRÜGER, Erwin A; FIGG, William D.Clinical cancer research. 2001, Vol 7, Num 7, pp 1867-1872, issn 1078-0432Article

UCN-01 suppresses E2F-1 mediated by ubiquitin-proteasome-dependent degradationHSUEH, Chung-Tsen; WU, Yu-Chung; SCHWARTZ, Gary K et al.Clinical cancer research. 2001, Vol 7, Num 3, pp 669-674, issn 1078-0432Article

Pharmacokinetics and pharmacodynamics of a novel protein kinase inhibitor, UCN-01KURATA, N; KUWABARA, T; TANII, H et al.Cancer chemotherapy and pharmacology. 1999, Vol 44, Num 1, pp 12-18, issn 0344-5704Article